Literature DB >> 25395390

Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.

Jiaojiao Jing1, Jan T Kielstein2, Ulla T Schultheiss1, Thomas Sitter3, Stephanie I Titze4, Elke S Schaeffner5, Mara McAdams-DeMarco6, Florian Kronenberg7, Kai-Uwe Eckardt4, Anna Köttgen1.   

Abstract

BACKGROUND: Reduced kidney function is a risk factor for hyperuricaemia and gout, but limited information on the burden of gout is available from studies of patients with chronic kidney disease (CKD). We therefore examined the prevalence and correlates of gout in the large prospective observational German Chronic Kidney Disease (GCKD) study.
METHODS: Data from 5085 CKD patients aged 18-74 years with an estimated glomerular filtration rate (eGFR) of 30-<60 mL/min/1.73 m(2) or eGFR ≥60 and overt proteinuria at recruitment and non-missing values for self-reported gout, medications and urate measurements from a central laboratory were evaluated.
RESULTS: The overall prevalence of gout was 24.3%, and increased from 16.0% in those with eGFR ≥60 mL/min/1.73 m(2) to 35.6% in those with eGFR <30. Of those with self-reported gout, 30.7% of individuals were not currently taking any gout medication and among gout patients on urate lowering therapy, 47.2% still showed hyperuricaemia. Factors associated with gout were serum urate, lower eGFR, advanced age, male sex, higher body mass index and waist-to-hip ratio, higher triglyceride and C-reactive protein (CRP) concentrations, alcohol intake and diuretics use. While lower eGFR categories showed significant associations with gout in multivariable-adjusted models (prevalence ratio 1.46 for eGFR <30 compared with eGFR ≥60, 95% confidence interval 1.21-1.77), associations between gout and higher urinary albumin-to-creatinine ratio in this CKD population were not significant.
CONCLUSIONS: Self-reported gout is common among patients with CKD and lower GFR is strongly associated with gout. Pharmacological management of gout in patients with CKD is suboptimal. Prospective follow-up will show whether gout and hyperuricaemia increase the risk of CKD progression and cardiovascular events in the GCKD study.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  GCKD study; chronic kidney disease; correlates; estimated glomerular filtration rate; gout epidemiology; observational study

Mesh:

Year:  2014        PMID: 25395390     DOI: 10.1093/ndt/gfu352

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  28 in total

1.  Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.

Authors:  Iris J M Disveld; Sahel Zoakman; Tim L Th A Jansen; Gerard A Rongen; Laura B E Kienhorst; Hein J E M Janssens; Jaap Fransen; Matthijs Janssen
Journal:  Clin Rheumatol       Date:  2019-03-30       Impact factor: 2.980

Review 2.  Managing Gout in the Patient with Renal Impairment.

Authors:  Eliseo Pascual; Francisca Sivera; Mariano Andrés
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

Review 3.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

Review 4.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 5.  [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency].

Authors:  L Sellin; J T Kielstein; K de Groot
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

Review 6.  Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms.

Authors:  Stefanie Steiger; Jan Rossaint; Alexander Zarbock; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2021-12-14       Impact factor: 10.121

Review 7.  The Interaction Between Dietary Fructose and Gut Microbiota in Hyperuricemia and Gout.

Authors:  Xin-Yu Fang; Liang-Wei Qi; Hai-Feng Chen; Peng Gao; Qin Zhang; Rui-Xue Leng; Yin-Guang Fan; Bao-Zhu Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Front Nutr       Date:  2022-06-22

8.  Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.

Authors:  James R O'Dell; Mary T Brophy; Michael H Pillinger; Tuhina Neogi; Paul M Palevsky; Hongsheng Wu; Anne Davis-Karim; Jeff A Newcomb; Ryan Ferguson; David Pittman; Grant W Cannon; Thomas Taylor; Robert Terkeltaub; Amy C Cannella; Bryant R England; Lindsay N Helget; Ted R Mikuls
Journal:  NEJM Evid       Date:  2022-02-03

9.  Risk factors of ultrasound-detected tophi in patients with gout.

Authors:  Beilei Lu; Qing Lu; Beijian Huang; Cuixian Li; Fengyang Zheng; Peilei Wang
Journal:  Clin Rheumatol       Date:  2020-02-15       Impact factor: 2.980

10.  Self-Reported Medication Use and Urinary Drug Metabolites in the German Chronic Kidney Disease (GCKD) Study.

Authors:  Fruzsina Kotsis; Ulla T Schultheiss; Matthias Wuttke; Pascal Schlosser; Johanna Mielke; Michael S Becker; Peter J Oefner; Edward D Karoly; Robert P Mohney; Kai-Uwe Eckardt; Peggy Sekula; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2021-06-17       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.